Highlights
- •A phase III clinical trial was performed for a novel botulinum toxin A, NABOTA, on post-stroke upper limb spasticity.
- •NABOTA demonstrated non-inferiority on efficacy and safety compared to onabotulinum toxin A (Botox).
- •NABOTA may serve as an alternative for treatment of post-stroke upper limb spasticity using botulinum toxin A.
Abstract
Botulinum toxin A is widely used in the clinics to reduce spasticity and improve upper
limb function for post-stroke patients. Efficacy and safety of a new botulinum toxin
type A, NABOTA (DWP450) in post-stroke upper limb spasticity was evaluated in comparison
with Botox (onabotulinum toxin A). A total of 197 patients with post-stroke upper
limb spasticity were included in this study and randomly assigned to NABOTA group
(n = 99) or Botox group (n = 98). Wrist flexors with modified Ashworth Scale (MAS) grade 2 or greater, and elbow
flexors, thumb flexors and finger flexors with MAS 1 or greater were injected with
either drug. The primary outcome was the change of wrist flexor MAS between baseline
and 4 weeks post-injection. MAS of each injected muscle, Disability Assessment Scale (DAS),
and Caregiver Burden Scale were also assessed at baseline and 4, 8, and 12 weeks after the injection. Global Assessment Scale (GAS) was evaluated on the last
visit at 12 weeks. The change of MAS for wrist flexor between baseline and 4 weeks post-injection was −1.44 ± 0.72 in the NABOTA group and −1.46 ± 0.77 in the Botox group. The difference of change between both groups was 0.0129 (95%
confidence interval −0.2062–0.2319), within the non-inferiority margin of 0.45. Both groups showed significant
improvements regarding MAS of all injected muscles, DAS, and Caregiver Burden Scale
at all follow-up periods. There were no significant differences in all secondary outcome
measures between the two groups. NABOTA demonstrated non-inferior efficacy and safety
for improving upper limb spasticity in stroke patients compared to Botox.
Abbreviations:
MAS (modified Ashworth Scale), DAS (Disability Assessment Scale), GAS (Global Assessment Scale), FAS (full analysis set), PPS (per protocol set)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prevalence of spasticity following stroke and its impact on quality of life with emphasis on disability in activities of daily living. Systematic review.Neurol. Neurochir. Pol. 2010; 44: 404-411
- Trends in the leading causes of death in Korea, 1983–2012.J. Korean Med. Sci. 2014; 29: 1597-1603
- Prevalence of spasticity post stroke.Clin. Rehabil. 2002; 16: 515-522
- Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review.Neurology. 2004; 63: 1357-1363
- Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.Neurology. 1996; 46: 1306-1310
- Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.N. Engl. J. Med. 2002; 347: 395-400
- Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: effect on impairment, activity limitation, and pain.Stroke. 2011; 42: 1371-1379
- Method for Production of Botulinum Toxin.2014 (Korea; PCT-KR2014-004003)
- Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle.Hum. Exp. Toxicol. 2013; 32: 914-920
- Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study.Int. J. Dermatol. 2015; 54: 227-234
- Interrater reliability of a modified Ashworth scale of muscle spasticity.Phys. Ther. 1987; 67: 206-207
- Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity.Arch. Phys. Med. Rehabil. 2002; 83: 1349-1354
- Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial.J. Neurol. Neurosurg. Psychiatry. 2000; 69: 217-221
- Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.Mov. Disord. 1998; 13: 150-154
- Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke.Arch. Phys. Med. Rehabil. 2004; 85: 1063-1069
- Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study.J. Neurol. Neurosurg. Psychiatry. 2009; 80: 380-385
- Efficacy of botulinum toxin a in upper limb function of hemiplegic patients.J. Neurol. 2002; 249: 76-84
Article info
Publication history
Published online: July 21, 2015
Accepted:
July 18,
2015
Received in revised form:
July 17,
2015
Received:
May 9,
2015
Footnotes
☆Clinical Trial Registration — URL://www.clinicaltrials.gov. Unique identifier: NCT02184988.
Identification
Copyright
© 2015 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
